Morgan Stanley Maintains Equal-Weight on Hologic, Raises Price Target to $76
Morgan Stanley analyst David Lewis maintains Hologic (NASDAQ:HOLX) with a Equal-Weight and raises the price target from $75 to $76.
Hologic Q4 Sales Fell On Lower COVID-19 Assay Sales; Guides FY22 Ahead Of Consensus
Hologic Inc (NASDAQ:HOLX) posted fourth-quarter revenues of $1.32 billion, down 2.3% Y/Y but beating analysts’ average estimate of $1.04 billion. The…
Earnings Scheduled For November 1, 2021
Companies Reporting Before The Bell
• ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Hologic Reports Its Multiplex COVID-19/Flu Test Now Commercially Available In North America, Europe
- Aptima® SARS-CoV-2/Flu Assay Tests Simultaneously for SARS-CoV-2, Influenza A and B on Fully Automated Panther® Molecular Diagnostics System -
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (NASDAQ:HOLX)
Redburn Partners Initiates Coverage On Hologic with Neutral Rating
Redburn Partners analyst Simon Baker initiates coverage on Hologic (NASDAQ:HOLX) with a Neutral rating.
Analyzing Hologic’s Unusual Options Activity
On Wednesday, shares of Hologic (NASDAQ:HOLX) saw unusual options activity. After the option alert, the stock price moved up to $76.64.
Raymond James Maintains Outperform on Hologic, Raises Price Target to $88
Raymond James analyst Andrew Cooper maintains Hologic (NASDAQ:HOLX) with a Outperform and raises the price target from $78 to $88.